Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.
Rhythm Biosciences Ltd announced the independent validation of its geneType Ovarian Cancer Risk Prediction Model through the Nurses’ Health Study, confirming its ability to identify twice as many women at elevated risk compared to clinical models alone. This validation supports the model’s clinical utility and aligns with the company’s strategy to enhance personalized and proactive disease management, potentially impacting early detection and prevention strategies in healthcare.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on delivering simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest stages, reducing the global cancer burden, and saving lives. Rhythm collaborates with global partners for the commercialization and distribution of its diagnostic solutions.
Average Trading Volume: 348,097
Technical Sentiment Signal: Buy
Current Market Cap: A$28.34M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.